Stock NOTV INOTIV, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Inotiv, Inc.

Equities

NOTV

US45783Q1004

Real-time Estimate Cboe BZX
Other stock markets
 02:54:47 2024-04-26 pm EDT 		5-day change 1st Jan Change
4.06 USD -5.36% Intraday chart for Inotiv, Inc. -6.02% +10.63%
Mar. 19 Inotiv, Inc. Elects Michael J. Harrington as Class III Member of the Board CI
Feb. 12 North American Morning Briefing : Stock Futures -2- DJ

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • The company presents an interesting fundamental situation from a short-term investment perspective.
  • The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

  • The company has a low valuation given the cash flows generated by its activity.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company has insufficient levels of profitability.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
INOTIV, INC. Stock Inotiv, Inc.
+10.63% 111M
D+
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.94% 42.59B
B
MODERNA, INC. Stock Moderna, Inc.
+8.26% 40.65B
B-
LONZA GROUP AG Stock Lonza Group AG
+49.22% 40.57B
A
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.77B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.88% 24.81B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.46% 18.17B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.71% 12.05B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.87% 11.7B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.78% 11.1B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NOTV Stock
  4. Ratings Inotiv, Inc.